Company Name Change and Headquarters Relocation

Tokyo, Japan – January 17, 2025 – CynosBio Inc. (formerly Hirosaki LI Inc.), a regenerative medicine company founded in 2015, today announced that it will officially change its corporate name and relocate its headquarters effective February 1, 2025.

The new company name “CynosBio” derives from “Cynosure,” meaning “a guiding light” or “the center of admiration.” The name reflects the company’s mission to become a beacon in life sciences and regenerative medicine while honoring the vision of its late founder, Sainojo Machida, whose pioneering spirit continues to guide the company.

The relocation to Nihonbashi, Tokyo, one of Japan’s most dynamic life science clusters specializing in urban innovation and business acceleration, marks an important step in CynosBio’s journey toward global expansion.

Since its founding, the company has collaborated with the Foundation for Biomedical Research and Innovation at Kobe (FBRI) to develop and manufacture regenerative medicine products. Its first approved product, Sakracy®, has been commercially available since 2022 for ocular surface adhesion reduction in limbal stem cell deficiency, and the company is now advancing clinical development of IK-01, an autologous cartilage cell product for knee cartilage regeneration.

With this name change and relocation, CynosBio will accelerate its global growth and continue to deliver cutting-edge regenerative therapies that restore the smiles of patients and families worldwide.